An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Gennao Bio Strengthens Board of Directors with Appointments of Peter Thompson, M.D., and Bradley Campbell
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
Rhea-AI Summary
Gennao Bio has appointed Peter Thompson, M.D., and Bradley Campbell to its Board of Directors. Peter Thompson brings extensive biotech experience in oncology and unmet medical needs, while Bradley Campbell has a strong background in orphan drug development. CEO Stephen Squinto expressed optimism about leveraging their expertise to advance Gennao's proprietary gene monoclonal antibody (GMAB) platform. The company aims to address significant needs in oncology and rare skeletal muscle diseases with its innovative, non-viral delivery system.
Positive
Appointment of seasoned biotech professionals may enhance strategic direction.
Expertise in oncology and rare diseases can bolster research and development efforts.
Negative
Potential concerns regarding continuity and experience gaps within the board.
HOPEWELL, N.J.--(BUSINESS WIRE)--
Gennao Bio, a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced the appointments of Peter Thompson, M.D., and Bradley Campbell to its Board of Directors.
“On behalf of the Board and management, we welcome Peter and Bradley to the Gennao team. Peter is a seasoned biotech entrepreneur with a proven track record of company creation and clinical development execution in oncology and other areas of unmet medical need. Bradley’s deep orphan drug development and commercialization experience will be an asset as we expand our pipeline research efforts in rare monogenic skeletal muscle diseases,” said Stephen Squinto, Ph.D., chief executive officer and chair of the board of Gennao Bio. “We look forward to leveraging their extensive expertise as we continue to advance the development of our proprietary, non-viral gene monoclonal antibody (GMAB) platform technology closer to the clinic.”
Dr. Thompson is a member at OrbiMed Advisors LLC, an investment firm. Dr. Thompson currently serves on the boards of directors of Alpine Immune Sciences Inc., Corvus Pharmaceuticals, Inc., Decibel Therapeutics, Inc., Edgewise Therapeutics, Inc., Janux Therapeutics, Inc., and Silverback Therapeutics, Inc., as well as several private companies. Previously, Dr. Thompson served on the boards of Synthorx Inc. until its acquisition by Sanofi, Adaptimmune Therapeutics PLC, PMV Pharmaceuticals, Inc., Prevail Therapeutics Inc., and Principia Biopharma Inc.Dr. Thompson also previously served in executive leadership roles at Trubion Pharmaceuticals, Inc., Chiron Corporation, and Becton, Dickinson and Company. Dr. Thompson is an Affiliate Professor of Neurosurgery at the University of Washington. In addition, Dr. Thompson holds numerous patents and is a board-certified internist and oncologist. Dr. Thompson holds a Sc. B. in molecular biology and mathematics from Brown University and an M.D. from Brown University Medical School.
Mr. Campbell is president and chief operating officer of Amicus Therapeutics and is also a member of its Board of Directors. On August 1, 2022, Mr. Campbell will succeed John F. Crowley as chief executive officer and will become president and chief executive officer of Amicus. Mr. Campbell joined Amicus in 2006 and leads the global organization responsible for the commercialization of Galafold®. He also oversees the corporate development, technical operations, market access, program management, clinical operations, and regulatory affairs functions. Mr. Campbell currently serves on the Board of the Association for Regenerative Medicine (ARM) and the Corporate Advisory Board for the National Tay-Sachs and Allied Diseases Association. Prior to Amicus, Mr. Campbell held various commercial and business development roles at Genzyme and Bristol-Myers Squibb and as a strategy consultant for Marakon Associates. He received a B.A. in public policy from Duke University and an MBA from Harvard Business School.
About Gennao Bio
Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology. GMAB is an adaptive technology that uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. This non-viral delivery platform is differentiated from traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing, and employs well-established manufacturing processes. Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases.
